Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

only hits with sugars are

10, 11, & 12

12 is my app.

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 02   STN pricing information for 2008 now available
 NEWS  3  JAN 16   CAS patent coverage enhanced to include exemplified
                   prophetic substances
 NEWS  4  JAN 28   USPATFULL, USPAT2, and USPATOLD enhanced with new
                   custom IPC display formats
 NEWS  5  JAN 28   MARPAT searching enhanced
 NEWS  6  JAN 28   USGENE now provides USPTO sequence data within 3 days
                   of publication
 NEWS  7  JAN 28   TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS  8  JAN 28   MEDLINE and LMEDLINE reloaded with enhancements
 NEWS  9  FEB 08   STN Express, Version 8.3, now available
 NEWS 10  FEB 20   PCI now available as a replacement to DPCI
 NEWS 11  FEB 25   IFIREF reloaded with enhancements
 NEWS 12  FEB 25   IMSPRODUCT reloaded with enhancements
 NEWS 13  FEB 29   WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                   U.S. National Patent Classification
 NEWS 14  MAR 31   IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                   IPC display formats
 NEWS 15  MAR 31   CAS REGISTRY enhanced with additional experimental
                   spectra
 NEWS 16  MAR 31   CA/CAplus and CASREACT patent number format for U.S.
                   applications updated
 NEWS 17  MAR 31   LPCI now available as a replacement to LDPCI
 NEWS 18  MAR 31   EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19  APR 04   STN AnaVist, Version 1, to be discontinued
 NEWS 20  APR 15   WPIDS, WPINDEX, and WPIX enhanced with new
                   predefined hit display formats
 NEWS 21  APR 28   EMBASE Controlled Term thesaurus enhanced
 NEWS 22  APR 28   IMSRESEARCH reloaded with enhancements
 NEWS 23  MAY 30   INPAFAMDB now available on STN for patent family
                   searching
 NEWS 24  MAY 30   DGENE, PCTGEN, and USGENE enhanced with new homology
                   sequence search option
 NEWS 25  JUN 06   EPFULL enhanced with 260,000 English abstracts
 NEWS 26  JUN 06   KOREAPAT updated with 41,000 documents
 NEWS 27  JUN 13   USPATFULL and USPAT2 updated with 11-character
                   patent numbers for U.S. applications
 NEWS 28  JUN 19   CAS REGISTRY includes selected substances from
                   web-based collections

 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.
```

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:24:11 ON 19 JUN 2008

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:24:29 ON 19 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 JUN 2008  HIGHEST RN 1029146-45-9
DICTIONARY FILE UPDATES:  18 JUN 2008  HIGHEST RN 1029146-45-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10529895.str

L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 17:24:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    30610 TO ITERATE

  6.5% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      601736 TO   622664
PROJECTED ANSWERS:              0 TO        0

L2             0 SEA SSS SAM L1

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
FULL SEARCH INITIATED 17:24:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   614862 TO ITERATE

100.0% PROCESSED   614862 ITERATIONS                          307 ANSWERS
SEARCH TIME: 00.00.09

L3          307 SEA SSS FUL L1

=> file caplus
```

```
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     178.57

FILE 'CAPLUS' ENTERED AT 17:25:08 ON 19 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 19 Jun 2008  VOL 148 ISS 25
FILE LAST UPDATED: 18 Jun 2008  (20080618/ED)
```



```
=> s l3
L4          30 L3

=> d bib abs hitstr 1-30 l4

L4   ANSWER 1 OF 30  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2008:419768  CAPLUS
DN   148:426885
TI   Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
     and their preparation, pharmaceutical compositions and use in the
     treatment of obesity and obesity-related metabolic disorders
IN   Lee, Jinhwa; Kim, Jeong Min; Chang, Chong-Hwan Jonathan; Lee, Suk Ho; Seo,
     Hee Jeong; Kang, Suk Youn; Song, Kwang-Seop; Kim, Jong Yup; Kim, Min-Ah;
     Lee, Sung-Han; Ahn, Kwang-Woo; Jung, Myung Eun; Park, Ji-Hyun
PA   Green Cross Corporation, S. Korea
SO   PCT Int. Appl., 281pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ------------------  ----   --------    ---------------------    --------
PI   WO 2008039023       A1     20080403    WO 2007-KR4754           20070928
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
     US 20080081815       A1     20080403    US 2006-541269           20060929
PRAI US 2006-541269       A      20060929
     KR 2006-132606       A      20061222
OS   MARPAT 148:426885
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *
```

AB A heteroaryl-pyrazole compound of formula I or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The invention also provides a method for preparing the inventive heteroaryl-pyrazole compds. or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders. Compds. of formula I wherein R1 is H, (un)substituted C1-5 alkyl, (un)substituted C2-4 alkenyl, (un)substituted C2-4 alkynyl, halo, etc.; R2 is H, NH2 and derivs., (un)substituted carbocycle, (un)substituted (hetero)aryl, (un)substituted heterocycle, etc.; R6, R7, R8, R9, R10, and R11 are independently H, halo, C1-3 alkyl, C1-3 alkoxy and CF3; X Y and Z are independently, =CR12, O, N=, NH and derivs., and S to form an aromatic heterocycle with Q and T; Q and T are independently C=, and N, with the proviso that both Q an T are not N at the same time; R12 are H, NH2 and derivative, (un)substituted carbocycle, (un)substituted (hetero)aryl, etc.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by hydrazination of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with butanoic acid hydrazide; the resulting N-butanoyl-N'-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl]hydrazine underwent microwave-mediated cyclization to give compound II. All the invention compds. were evaluated for their CB1 antagonistic activity (some data given).

IT 1016553-07-3P 1016553-08-4P 1016553-09-5P
1016553-12-0P 1016553-13-1P 1016553-14-2P
1016553-15-3P 1016553-16-4P 1016553-17-5P
1016553-18-6P 1016553-19-7P 1016553-20-0P
1016553-21-1P 1016553-22-2P 1016553-27-7P
1016553-28-8P 1016553-29-9P 1016553-30-2P
1016553-31-3P 1016553-33-5P 1016553-34-6P
1016553-35-7P 1016553-36-8P 1016553-37-9P
1016553-38-0P 1016553-39-1P 1016553-40-4P
1016553-41-5P 1016553-42-6P 1016553-43-7P
1016553-44-8P 1016553-45-9P 1016553-46-0P
1016553-47-1P 1016555-30-8P 1016555-32-0P
1016555-34-2P 1016555-36-4P 1016555-37-5P
1016555-39-7P 1016555-41-1P 1016555-43-3P
1016555-44-4P 1016555-45-5P 1016555-47-7P
1016555-49-9P 1016555-51-3P 1016555-52-4P
1016555-53-5P 1016555-55-7P 1016555-56-8P
1016555-58-0P 1016557-46-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroaryl-pyrazole derivs. as cannabinoid CB1 receptor antagonists useful in the treatment of obesity and obesity-related metabolic disorders)

RN 1016553-07-3 CAPLUS

CN Piperidine, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 1016553-08-4 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1-pyrrolidinylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-09-5 CAPLUS
CN Morpholine, 4-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-12-0 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-13-1 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-imidazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-14-2 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-pyrazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-15-3 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-pyrrol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-16-4 CAPLUS
CN 1H-Tetrazole, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-17-5 CAPLUS
CN 2H-Tetrazole, 2-[[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-18-6 CAPLUS
CN 1H-Tetrazole, 1-[[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-19-7 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,3-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-20-0 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-21-1 CAPLUS
CN 2-Pyrrolidinone, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-22-2 CAPLUS
CN 2-Oxazolidinone, 3-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-27-7 CAPLUS
CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-(CA INDEX NAME)



RN 1016553-28-8 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]-(CA INDEX NAME)



RN 1016553-29-9 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclobutyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016553-30-2 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclohexyl- (CA INDEX NAME)



RN 1016553-31-3 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 1016553-33-5 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methylphenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-34-6 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methoxyphenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-35-7 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(2,4-dichlorophenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-36-8 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016553-37-9 CAPLUS
CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016553-38-0 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopentyl)- (CA INDEX NAME)



RN 1016553-39-1 CAPLUS
CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclopentyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1016553-40-4 CAPLUS
CN 1,3,4-Oxadiazole, 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-41-5 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX NAME)



RN 1016553-42-6 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-43-7 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-chlorophenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-44-8 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-45-9 CAPLUS
CN 2H-Tetrazole, 5-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-46-0 CAPLUS
CN 2H-Tetrazole, 5-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]-2-methyl- (CA INDEX NAME)



RN 1016553-47-1 CAPLUS

CN 1H-Tetrazole, 5-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]-1-methyl- (CA INDEX NAME)



RN 1016555-30-8 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016555-32-0 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016555-34-2 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclobutyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016555-36-4 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclohexyl- (CA INDEX NAME)



RN 1016555-37-5 CAPLUS
CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1016555-39-7 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 1016555-41-1 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methylphenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-43-3 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methoxyphenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-44-4 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(2,4-dichlorophenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-45-5 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-47-7 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016555-49-9 CAPLUS
CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-

(CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016555-51-3 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopentyl)- (CA INDEX NAME)



RN 1016555-52-4 CAPLUS
CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclopentyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1016555-53-5 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX NAME)



RN 1016555-55-7 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-56-8 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-chlorophenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-58-0 CAPLUS
CN 1,3,4-Thiadiazole, 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016557-46-2 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:416137 CAPLUS
DN 148:426884
TI Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of obesity and obesity-related metabolic disorders
IN Lee, Jinhwa; Kim, Jeong Min; Chang, Chong-Hwan Jonathan; Lee, Suk Ho; Seo, Hee Jeong; Kang, Suk Youn; Song, Kwang-Seop; Kim, Jong Yup; Kim, Min-Ah; Lee, Sung-Han; Ahn, Kwang-Woo; Jung, Myung Eun; Park, Ji-Hyun
PA Green Cross Corporation, S. Korea
SO U.S. Pat. Appl. Publ., 124pp., Cont.-in-part of U. S. Ser. No. 541,269.
CODEN: USXXCO
DT Patent

LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 20080081812 | A1 | 20080403 | US 2007-863501 | 20070928 |
| | US 20080081815 | A1 | 20080403 | US 2006-541269 | 20060929 |
| PRAI | US 2006-541269 | A2 | 20060929 | | |

OS MARPAT 148:426884
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A heteroaryl-pyrazole compound of formula I or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The invention also provides a method for preparing the inventive heteroaryl-pyrazole compds. or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders. Compds. of formula I wherein R1 is H, (un)substituted C1-5 alkyl, (un)substituted C2-4 alkenyl, (un)substituted C2-4 alkynyl, halo, etc.; R2 is H, NH2 and derivs., (un)substituted carbocycle, (un)substituted (hetero)aryl, (un)substituted heterocycle, etc.; R6, R7, R8, R9, R10, and R11 are independently H, halo, C1-3 alkyl, C1-3 alkoxy and CF3; X Y and Z are independently, =CR12, O, N=, NR and derivs., and S to form an aromatic heterocycle with Q and T; Q and T are independently C=, and N, with the proviso that both Q an T are not N at the same time; R12 are H, NH2 and derivative, (un)substituted carbocycle, (un)substituted (hetero)aryl, etc.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by hydrazination of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with butanoic acid hydrazide; the resulting N-butanoyl-N'-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl]hydrazine underwent microwave-mediated cyclization to give compound II. All the invention compds. were evaluated for their CB1 antagonistic activity (some data given).

IT 1016553-07-3P 1016553-08-4P 1016553-09-5P
1016553-12-0P 1016553-13-1P 1016553-14-2P
1016553-15-3P 1016553-16-4P 1016553-17-5P
1016553-18-6P 1016553-19-7P 1016553-20-0P
1016553-21-1P 1016553-22-2P 1016553-27-7P
1016553-28-8P 1016553-29-9P 1016553-30-2P
1016553-31-3P 1016553-33-5P 1016553-34-6P
1016553-35-7P 1016553-36-8P 1016553-37-9P
1016553-38-0P 1016553-39-1P 1016553-40-4P
1016553-41-5P 1016553-42-6P 1016553-43-7P
1016553-44-8P 1016553-45-9P 1016553-46-0P
1016553-47-1P 1016555-30-8P 1016555-32-0P
1016555-34-2P 1016555-36-4P 1016555-37-5P
1016555-39-7P 1016555-41-1P 1016555-43-3P
1016555-44-4P 1016555-45-5P 1016555-47-7P
1016555-49-9P 1016555-51-3P 1016555-52-4P
1016555-53-5P 1016555-55-7P 1016555-56-8P
1016555-58-0P 1016557-46-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroaryl-pyrazole derivs. as cannabinoid CB1 receptor antagonists useful in the treatment of obesity and obesity-related metabolic disorders)

RN 1016553-07-3 CAPLUS

CN Piperidine, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-08-4 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1-pyrrolidinylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-09-5 CAPLUS
CN Morpholine, 4-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-12-0 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-13-1 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-imidazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-14-2 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-pyrazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-15-3 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-pyrrol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-16-4 CAPLUS
CN 1H-Tetrazole, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-17-5 CAPLUS
CN 2H-Tetrazole, 2-[[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-18-6 CAPLUS
CN 1H-Tetrazole, 1-[[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-19-7 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,3-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-20-0 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-21-1 CAPLUS
CN 2-Pyrrolidinone, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-22-2 CAPLUS
CN 2-Oxazolidinone, 3-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-27-7 CAPLUS
CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1016553-28-8 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-29-9 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclobutyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016553-30-2 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclohexyl- (CA INDEX NAME)



RN 1016553-31-3 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 1016553-33-5 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methylphenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-34-6 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methoxyphenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-35-7 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(2,4-dichlorophenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-36-8 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016553-37-9 CAPLUS
CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)

PAGE 1-A



RN 1016553-38-0 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopentyl)- (CA INDEX NAME)



RN 1016553-39-1 CAPLUS
CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclopentyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1016553-40-4 CAPLUS
CN 1,3,4-Oxadiazole, 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-41-5 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX NAME)



RN 1016553-42-6 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-43-7 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-chlorophenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-44-8 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-45-9 CAPLUS
CN 2H-Tetrazole, 5-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-46-0 CAPLUS
CN 2H-Tetrazole, 5-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]-2-methyl- (CA INDEX NAME)



RN 1016553-47-1 CAPLUS

CN 1H-Tetrazole, 5-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]-1-methyl- (CA INDEX NAME)



RN 1016555-30-8 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016555-32-0 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016555-34-2 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclobutyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016555-36-4 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclohexyl- (CA INDEX NAME)



RN 1016555-37-5 CAPLUS
CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1016555-39-7 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 1016555-41-1 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methylphenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-43-3 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methoxyphenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-44-4 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(2,4-dichlorophenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-45-5 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-47-7 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016555-49-9 CAPLUS
CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-

(CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1016555-51-3 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopentyl)- (CA INDEX NAME)



RN 1016555-52-4 CAPLUS
CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclopentyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1016555-53-5 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX NAME)



RN 1016555-55-7 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-56-8 CAPLUS
CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-chlorophenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-58-0 CAPLUS
CN 1,3,4-Thiadiazole, 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016557-46-2 CAPLUS
CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX NAME)



L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1177863 CAPLUS
DN 147:469247
TI Preparation of quinolones derivatives useful as inducible nitric oxide synthase inhibitors
IN Roppe, Jeffrey R.; Bonnefous, Celine; Smith, Nicholas D.; Lindstrom, Andrew K.; Noble, Stewart A.; Hassig, Christian A.; Payne, Joseph E.; Zhuang, Hui; Chen, Xiaohong; Duron, Sergio G.
PA Kalypsys, Inc., USA
SO PCT Int. Appl., 238pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

| | | | | | |
|---|---|---|---|---|---|
| PI | WO 2007117778 | A2 | 20071018 | WO 2007-US62769 | 20070223 |
| | WO 2007117778 | A3 | 20080207 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | |
| | US 20080139558 | A1 | 20080612 | US 2007-678572 | 20070223 |
| PRAI | US 2006-776561P | P | 20060224 | | |
| | US 2006-848696P | P | 20061002 | | |
| OS | MARPAT 147:469247 | | | | |
| GI | | | | | |




AB The invention relates to novel quinolones of formula I [R1 = (un)substituted acyl, alkyl, alkylene, aminoalkyl, amidoalkyl, alkynyl, aryl, arylalkyl, arylalkoxy, etc.; R2 = (un)substituted acyl, alkoxy, alkoxyalkyl, alkyl, alkylene, alkylamino, alkynyl, alkylimino, etc.; R2 may combine with R1 to form (un)substituted heterocycloalkyl; R3 = H, NH2, (un)substituted aryl, haloalkyl, (hetero)arylalkyl, (hetero)(cyclo)alkyl; A, B, C and D independently = (un)substituted acyl, alkoxy, alkyl, alkylene, alkylamino, alkynyl, etc.; any two or more A, B, C and D may combine to form aryl, cycloalkyl, heteroaryl or heterocycloalkyl], and their pharmaceutically acceptable salts, esters or prodrugs, are prepared and disclosed as inducible nitric oxide synthase (iNOS) inhibitors. Thus, e.g. II was prepared by acylation of aniline with Et 3-oxobutanoate followed by bromination and cyclization to generate intermediate 4-(bromomethyl)quinolin-2(1H)-one, which underwent substitution with aniline and acylation with furan-2-carbonyl chloride to provide II. The inhibitory activity of all exemplary compds. was evaluated in DAN assay and II was found to have EC50 value of ≤ 5 μM. I should prove useful for inhibiting or modulating nitric oxide synthase and/or lowering nitric oxide levels of iNOS and for the treatment of an iNOS-mediated disease in a patient in need thereof.

IT 953068-15-0P, 4-[[3-(3-Chlorophenyl)-5-(4-methylthiazol-5-yl)-1H-pyrazol-4-yl]methyl]-8-fluoroquinolin-2(1H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolones derivs. useful as inducible nitric oxide synthase inhibitors)

RN 953068-15-0 CAPLUS

CN 2(1H)-Quinolinone, 4-[[3-(3-chlorophenyl)-5-(4-methyl-5-thiazolyl)-1H-pyrazol-4-yl]methyl]-8-fluoro- (CA INDEX NAME)



L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:744384 CAPLUS
DN 148:483659
TI Bis(μ-4-benzyl-3,5-diphenylpyrazolato-κ2N:N')bis[(4,4'-dimethyl-2,2'-bipyridine-κ2N,N')palladium(II)] bis(hexafluorophosphate) diethyl ether monosolvate monohydrate
AU Huang, Hai-Ping; Liu, Li-Xia
CS Laboratory for Self-Assembly Chemistry, Department of Chemistry, Renmin University of China, Beijing, 100872, Peop. Rep. China
SO Acta Crystallographica, Section E: Structure Reports Online (2007), E63(7), m1875-m1876
CODEN: ACSEBH; ISSN: 1600-5368
URL: http://journals.iucr.org/e/issues/2007/07/00/si2018/si2018.pdf
PB Blackwell Publishing Ltd.
DT Journal; (online computer file)
LA English
AB In the crystal structure of the title compound, [Pd2(C22H17N2)2(C12H12N2)2](PF6)2·C4H10O·H2O, two Pd(dmbpy) units (dmbpy is 4,4'-dimethyl-2,2'-bipyridine) are bridged by 4-benzyl-3,5-diphenylpyrazolate ligands in an exodentate fashion, which results in a clip-like cavity between the two Pd(dmbpy)Pd planes. A disordered hexafluoridophosphate anion is held in the cavity by an anion-π interaction [P-F···Cg1 = 3.435(15) Å (Cg1 is the centroid of the Pd-dmbpy chelate ring system) and P-F···Cg2 = 3.187(15) Å (Cg2 is the centroid of a pyridine ring)]. A crystallog. 2-fold rotation axis passes through an F atom of the disordered anion and the mid-point of the two Pd atoms. The P and two F atoms of the 2nd anion also lie on a 2-fold rotation axis, as do the O atom of the Et2O and the water O atom. The crystal structure is stabilized by electrostatic forces between the cations and anions, and intermol. H bonds involving hexafluoridophosphate anions (C-H···F), the solvent Et2O mols. and H2O mols. (C-H···O). Crystallog. data and atomic coordinates are given.
IT 1020667-43-9P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (crystal structure of)
RN 1020667-43-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 60-29-7
CMF C4 H10 O

$H_3C-CH_2-O-CH_2-CH_3$

CM 2

CRN 1020667-42-8
CMF C68 H58 N8 Pd2 . 2 F6 P

CM 3

CRN 1020667-41-7
CMF C68 H58 N8 Pd2
CCI CCS



CM 4

CRN 16919-18-9
CMF F6 P
CCI CCS

IT 955955-05-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of palladium dimethylbipyridine nitrato complex with benzyldiphenylpyrazole in aqueous solution followed by addition of potassium hexafluorophosphate)
RN 955955-05-2 CAPLUS
CN 1H-Pyrazole, 3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:626543 CAPLUS
DN 148:296308
TI 4-[(3,5-Diphenyl-1H-pyrazol-4-yl)methyl]benzonitrile ethanol hemisolvate
AU Yu, Mei
CS Institute of Biomedical Engineering, Chinese Academy of Medical Sciences, Tianjin, 300192, Peop. Rep. China
SO Acta Crystallographica, Section E: Structure Reports Online (2007), E63(6), o2863
CODEN: ACSEBH; ISSN: 1600-5368

URL: http://journals.iucr.org/e/issues/2007/06/00/hg2234/hg2234.pdf
PB Blackwell Publishing Ltd.
DT Journal; (online computer file)
LA English
AB In 4-[(3,5-diphenyl-1H-pyrazol-4-yl)methyl]benzonitrile hemiethanolate, C23H17N3·0.5C2H6O, 2 pyrazole mols. are bridged by 1 EtOH mol. through N-H···O and O-H···N H bonds. The EtOH solvent mol. is located on a mirror plane. These trimol. units are linked by C-H···N, N-H···O and H bonds involving the nitrile groups and EtOH OH as acceptors and C-H···π stacking interactions between Ph groups. Crystallog. data are given.
IT 1007840-65-4
RL: PRP (Properties)
(crystal and mol. structure of)
RN 1007840-65-4 CAPLUS
CN Benzonitrile, 4-[(3,5-diphenyl-1H-pyrazol-4-yl)methyl]-, compd. with ethanol (2:1) (CA INDEX NAME)

CM 1

CRN 1007840-64-3
CMF C23 H17 N3



CM 2

CRN 64-17-5
CMF C2 H6 O

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:242471 CAPLUS
DN 147:511993
TI 4-Benzyl-3,5-diphenyl-1H-pyrazole
AU Huang, Hai-Ping; Wu, Qiong; Liu, Li-Xia; Sun, Qing-Fu
CS Laboratory for Self-Assembly Chemistry, Department of Chemistry, Renmin University of China, Beijing, 100872, Peop. Rep. China
SO Acta Crystallographica, Section E: Structure Reports Online (2007), E63(3), o1473-o1474
CODEN: ACSEBH; ISSN: 1600-5368
URL: http://journals.iucr.org/e/issues/2007/03/00/hg2185/hg2185.pdf
PB Blackwell Publishing Ltd.
DT Journal; (online computer file)
LA English
OS CASREACT 147:511993
AB The mols. of 4-benzyl-3,5-diphenyl-1H-pyrazole, C22H18N2, are connected by N-H···N H bonds, forming cyclic dimers. These dimers are linked by C-H···π H bonds involving the Ph rings as acceptors. Crystallog. data are given.
IT 955955-05-2P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal and mol. structure of)
RN 955955-05-2 CAPLUS
CN 1H-Pyrazole, 3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:36895 CAPLUS
DN 146:142641
TI Preparation of substituted 1-sulfolanyl-1H-pyrazoles as anti-AIDS agents
IN Paessens, Arnold; Schohe-Loop, Rudolf; Bauser, Marcus; Jeske, Mario; Koebberling, Johannes; Henninger, Kerstin; Lang, Dieter; Welker, Reinhold; Paulsen, Daniela
PA Aicuris G.m.b.H. & Co. K.-G., Germany
SO PCT Int. Appl., 94pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2007003389 | A2 | 20070111 | WO 2006-EP6430 | 20060701 |
| WO 2007003389 | A3 | 20070419 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| DE 102005031580 | A1 | 20070111 | DE 2005-102005031580 | 20050706 |
| PRAI DE 2005-102005031580 A | | 20050706 | | |

OS MARPAT 146:142641
GI



AB The title compds. [I; R1, R2 = (substituted) Ph, 5-6 membered heteroaryl; R3 = (substituted) Ph, 5-10 heteroaryl] were prepared Thus,

3-[[1-(1,1-dioxidotetrahydro-3-thienyl)-5-phenyl-3-pyridin-2-yl-1H-pyrazol-4-yl]methyl]benzoic acid (preparation given) in DMF was stirred with 4-aminopyridine, HATU and Et3N for 2 h at room temperature to give 46% 3-[[1-(1,1-dioxidotetrahydro-3-thienyl)-5-phenyl-3-pyridin-2-yl-1H-pyrazol-4-yl]methyl]-N-pyridin-4-ylbenzamide. The latter protected H9 cells from HIV-induced destruction with IC50 = 0.05 μM at 2% FCS.

IT 919095-57-1P
RL: BYP (Byproduct); PREP (Preparation)
(preparation of substituted sulfolanylpyrazoles as anti-AIDS agents)

RN 919095-57-1 CAPLUS

CN Benzoic acid, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, methyl ester (CA INDEX NAME)



IT 919095-64-0P 919095-65-1P 919095-66-2P
919095-67-3P 919095-68-4P 919095-69-5P
919095-70-8P 919095-71-9P 919095-72-0P
919095-73-1P 919095-74-2P 919095-75-3P
919095-76-4P 919095-77-5P 919095-78-6P
919095-79-7P 919095-80-0P 919095-81-1P
919095-82-2P 919095-83-3P 919095-84-4P
919095-85-5P 919095-86-6P 919095-87-7P
919095-88-8P 919095-89-9P 919095-90-2P
919095-91-3P 919095-92-4P 919095-93-5P
919095-94-6P 919095-95-7P 919095-96-8P
919095-97-9P 919095-98-0P 919095-99-1P
919096-00-7P 919096-01-8P 919096-03-0P
919096-05-2P 919096-07-4P 919096-09-6P
919096-11-0P 919096-13-2P 919096-15-4P
919096-16-5P 919096-18-7P 919096-19-8P
919096-20-1P 919096-21-2P 919096-22-3P
919096-23-4P 919096-24-5P 919096-64-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted sulfolanylpyrazoles as anti-AIDS agents)

RN 919095-64-0 CAPLUS

CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-4-pyridinyl- (CA INDEX NAME)



RN 919095-65-1 CAPLUS

CN Benzamide, N-(2-chlorophenyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-66-2 CAPLUS
CN Benzamide, N-(3-methylphenyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-67-3 CAPLUS
CN Benzamide, N-(3-chlorophenyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-68-4 CAPLUS
CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-pyridinyl- (CA INDEX NAME)



RN 919095-69-5 CAPLUS
CN Benzamide, N-phenyl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-70-8 CAPLUS
CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 919095-71-9 CAPLUS
CN Benzamide, N-(2-methyl-4-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-72-0 CAPLUS
CN Benzamide, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-pyridinyl- (CA INDEX NAME)



RN 919095-73-1 CAPLUS
CN Benzamide, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 919095-74-2 CAPLUS
CN Benzamide, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-4-pyridinyl- (CA INDEX NAME)



RN 919095-75-3 CAPLUS
CN Benzamide, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-(2-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 919095-76-4 CAPLUS
CN Benzamide, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-(2,6-dimethyl-4-pyridinyl)- (CA INDEX NAME)



RN 919095-77-5 CAPLUS
CN Benzamide, 3-[[5-(2-furanyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-pyridinyl- (CA INDEX NAME)



RN 919095-78-6 CAPLUS
CN Benzamide, 3-[[5-(2-furanyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 919095-79-7 CAPLUS
CN Benzamide, 3-[[5-(2-furanyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-4-pyridinyl- (CA INDEX NAME)



RN 919095-80-0 CAPLUS
CN Benzamide, 3-[[5-(2-furanyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-(2-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 919095-81-1 CAPLUS
CN Benzamide, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-pyridinyl- (CA INDEX NAME)



RN 919095-82-2 CAPLUS
CN Benzamide, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 919095-83-3 CAPLUS
CN Benzamide, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-4-pyridinyl- (CA INDEX NAME)



RN 919095-84-4 CAPLUS
CN Benzamide, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-(2-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 919095-85-5 CAPLUS
CN Benzamide, N-1H-benzimidazol-6-yl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-86-6 CAPLUS
CN Benzamide, N-1H-benzotriazol-6-yl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-87-7 CAPLUS
CN Benzamide, N-(5-methyl-3-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-88-8 CAPLUS
CN Benzamide, N-1H-indazol-6-yl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-89-9 CAPLUS
CN Benzamide, N-(6-ethyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-90-2 CAPLUS
CN Benzamide, N-(6-fluoro-5-methyl-3-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-91-3 CAPLUS
CN Benzamide, N-(5-methyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-92-4 CAPLUS
CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-thiazolyl- (CA INDEX NAME)



RN 919095-93-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-94-6 CAPLUS
CN Benzamide, N-(2-ethyl-4-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-95-7 CAPLUS
CN Benzamide, N-(4-methyl-2-thiazolyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-96-8 CAPLUS
CN Benzamide, N-(5-methyl-2-thiazolyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-97-9 CAPLUS

CN Benzamide, N-1H-indazol-7-yl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-98-0 CAPLUS
CN Benzamide, N-(6-methoxy-3-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-99-1 CAPLUS
CN Benzamide, N-(6-amino-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-00-7 CAPLUS
CN Benzamide, N-(1-oxido-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-01-8 CAPLUS
CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-4-pyrimidinyl- (CA INDEX NAME)



RN 919096-03-0 CAPLUS
CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-pyrazinyl- (CA INDEX NAME)



RN 919096-05-2 CAPLUS
CN Benzamide, N-(6-methyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-07-4 CAPLUS
CN Benzamide, N-(5-fluoro-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-09-6 CAPLUS
CN Benzamide, N-[1-(methoxymethyl)-1H-pyrazol-4-yl]-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-11-0 CAPLUS
CN Benzamide, N-(4-methyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-13-2 CAPLUS
CN Benzamide, N-(4-ethyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-15-4 CAPLUS
CN Benzamide, N-(5-methyl-1,3,4-thiadiazol-2-yl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-16-5 CAPLUS
CN Benzamide, N-(4,6-dimethyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-18-7 CAPLUS
CN Benzamide, N-[5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-19-8 CAPLUS
CN Benzamide, N-(4,5-dimethyl-2-oxazolyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-20-1 CAPLUS
CN Benzamide, N-(1,3-dimethyl-1H-pyrazol-5-yl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-21-2 CAPLUS
CN Benzamide, N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-22-3 CAPLUS
CN Benzamide, N-1H-indol-4-yl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-23-4 CAPLUS
CN Benzamide, N-(2,6-dimethyl-4-pyrimidinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-24-5 CAPLUS
CN Benzamide, N-(3-methyl-5-isoxazolyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-64-3 CAPLUS
CN Benzamide, N-(6-chloro-3-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



IT 919095-54-8P 919095-55-9P 919095-56-0P
919095-58-2P 919095-59-3P 919095-60-6P
919095-61-7P 919095-62-8P 919095-63-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted sulfolanylpyrazoles as anti-AIDS agents)
RN 919095-54-8 CAPLUS
CN Benzoic acid, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 919095-55-9 CAPLUS
CN Benzoic acid, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 919095-56-0 CAPLUS
CN Benzoic acid, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 919095-58-2 CAPLUS
CN Benzoic acid, 3-[[3-(2-furanyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 919095-59-3 CAPLUS
CN Benzoic acid, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-60-6 CAPLUS
CN Benzoic acid, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 919095-59-3
CMF C26 H23 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 919095-61-7 CAPLUS
CN Benzoic acid, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-62-8 CAPLUS
CN Benzoic acid, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-63-9 CAPLUS
CN Benzoic acid, 3-[[5-(2-furanyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:661832 CAPLUS
DN 145:292940
TI Synthesis of pyrazoles by treatment of 3-benzylchromones, 3-benzylflavones and their 4-thio analogues with hydrazine
AU Levai, Albert; Silva, Artur M. S.; Cavaleiro, Jose A. S.; Alkorta, Ibon; Elguero, Jose; Jeko, Jozsef
CS Department of Organic Chemistry, University of Debrecen, Debrecen, 4010, Hung.
SO European Journal of Organic Chemistry (2006), (12), 2825-2832
CODEN: EJOCFK; ISSN: 1434-193X
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OS CASREACT 145:292940
AB The synthesis of pyrazoles has been accomplished by treatment of 3-benzylchromones, 3-benzylflavones and their 4-thio analogs with hydrazine hydrate in hot pyridine. A plausible reaction mechanism for the formation of pyrazoles was discussed. A 1H NMR study in [D6]DMSO allowed the presence of both pyrazole annular tautomers to be observed, due to the presence of intramol. hydrogen bonds in each tautomer (OH--N and NH--O). GIAO/B3LYP/6-311++G** calcns. were carried out on some model pyrazoles to provide a theor. basis for the NMR exptl. observations.
IT 908252-19-7P 908252-20-0P 908252-21-1P
908252-23-3P 908252-24-4P 908252-25-5P
908252-26-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted pyrazoles via heterocyclization of benzylchromones and benzothiochromones with hydrazine)
RN 908252-19-7 CAPLUS
CN Phenol, 2-[4-[(2-chlorophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 908252-20-0 CAPLUS
CN Phenol, 2-[4-[(3-chlorophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 908252-21-1 CAPLUS
CN Phenol, 2-[4-[(4-chlorophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 908252-23-3 CAPLUS
CN Phenol, 2-[4-[(4-bromophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 908252-24-4 CAPLUS
CN Phenol, 2-[4-[(4-nitrophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 908252-25-5 CAPLUS
CN Phenol, 2-[4-[(2,4-dichlorophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 908252-26-6 CAPLUS
CN Phenol, 2-[4-[(3,4-dichlorophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:219796 CAPLUS
DN 142:280203
TI Preparation of bicyclic pyrazole derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors
IN Nakahira, Hiroyuki; Hochigai, Hitoshi; Takeda, Tatsuya; Kobayashi, Tomonori; Hume, William Ewan

PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO PCT Int. Appl., 252 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
PAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2005021550 | A1 | 20050310 | WO 2004-JP12617 | 20040825 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1659123 | A1 | 20060524 | EP 2004-772573 | 20040825 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| US 20070082908 | A1 | 20070412 | US 2006-595125 | 20060227 |
| PRAI JP 2003-306948 | A | 20030829 | | |
| WO 2004-JP12617 | W | 20040825 | | |

OS MARPAT 142:280203
GI







AB The title compds. I [R1 represents hydrogen, optionally substituted alkyl, etc.; the solid line and dotted line between A and A1 represent a double bond or a single bond; A represents a group represented by the formula C(R2), etc.; A1 represents a group represented by the formula C(R4), etc.; R2 represents hydrogen, optionally substituted alkyl, etc.; R4 represents hydrogen, optionally substituted alkyl, etc.; R6 represents hydrogen, optionally substituted aryl, etc.; and Y represents, e.g., a group represented by the formula Q1 (wherein A' represents (CH2)m1; m1 is 0, 1, 2, or 3; and R7 is absent, or one or two R7's are present and each independently represents optionally substituted alkyl, etc.),] are prepared Et 3-(but-2-yn-1-yl)-4-oxo-2-(piperazin-1-yl)-4,5-dihydropyrazolo[1,5-a]pyrazine-6-carboxylate hydrochloride was prepared by heating a solution of II in 1,4-dioxane containing HCl and water at 50°C for 2.5 h. Compds. of this invention in vitro showed IC50 values of 0.9 nM to 82 nM against human DPP-IV.

IT 847492-77-7P 847492-78-8P 847492-79-9P
847492-80-2P 847492-81-3P 847492-82-4P

847492-83-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic pyrazole derivs. as dipeptidyl peptidase IV inhibitors)

RN 847492-77-7 CAPLUS
CN L-Proline, 1-[[4-[(2-chlorophenyl)methyl]-5-[(3R)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-1-(methoxymethyl)-1H-pyrazol-3-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 847492-78-8 CAPLUS
CN L-Proline, 1-[[4-[(2-chlorophenyl)methyl]-5-[(3R)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-1-(methoxymethyl)-1H-pyrazol-3-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847492-79-9 CAPLUS
CN Carbamic acid, [(3R)-1-[4-[(2-chlorophenyl)methyl]-1-(methoxymethyl)-3-[[2-[(methoxymethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-1H-pyrazol-5-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847492-80-2 CAPLUS
CN Carbamic acid, [(3R)-1-[3-[(2-acetyl-1-pyrrolidinyl)carbonyl]-4-[(2-chlorophenyl)methyl]-1-(methoxymethyl)-1H-pyrazol-5-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847492-81-3 CAPLUS
CN L-Proline, 1-[[4-[(2-chlorophenyl)methyl]-5-[(3R)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-1-(methoxymethyl)-1H-pyrazol-3-yl]carbonyl]-4-fluoro-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847492-82-4 CAPLUS
CN L-Proline, 1-[[4-[(2-chlorophenyl)methyl]-5-[(3R)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-1-(methoxymethyl)-1H-pyrazol-3-yl]carbonyl]-4-fluoro-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847492-83-5 CAPLUS
CN Carbamic acid, [(3R)-1-[4-[(2-chlorophenyl)methyl]-3-[[(2S,4S)-4-fluoro-2-[(methoxymethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-1-(methoxymethyl)-1H-pyrazol-5-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:1156566 CAPLUS
DN 142:94061
TI Preparation of pyrazole glycoside compounds as SGLT inhibitors
IN Kikuchi, Norihiko; Fujikura, Hideki; Tazawa, Shigeki; Yamato, Tokuhisa; Isaji, Masayuki
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2004113359 | A1 | 20041229 | WO 2004-JP8695 | 20040615 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2529878 | A1 | 20041229 | CA 2004-2529878 | 20040615 |
| | EP 1637539 | A1 | 20060322 | EP 2004-746165 | 20040615 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | US 20070060531 | A1 | 20070315 | US 2006-561217 | 20061113 |
| PRAI | JP 2003-175663 | A | 20030620 | | |
| | WO 2004-JP8695 | W | 20040615 | | |

OS MARPAT 142:94061
GI



I



II

AB Title compds. I [R1 = H, (un)substituted alkyl, etc.; one of Q and T is II, etc.; the other is Z-Ar; Z = O, etc.; Ar = aryl, etc.; R = (un)substituted cycloalkyl, etc.] were prepared For example, glycosidation of 1-isopropyl-4-(4-methoxybenzyl)-5-phenoxyl-1,2-dihydro-3H-pyrazol-3-one by 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl bromide in the presence of benzyltributylammonium chloride followed by deacetylation using sodium methoxide afforded compound I [R1 = isopropyl; R = 4-methoxyphenyl; Q = phenoxy; T = II]. In SMINT inhibition assays, the IC50 value of compound I [R1 = isopropyl; R = 4-methoxyphenyl; Q = phenoxy; T = II] was 700 nM. Of note, compds. I have SGLT inhibition activity (no data provided). Compds. I are claimed useful for the treatment of diabetes, obesity, etc.

IT 815581-51-2P 815581-53-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole glycoside compds. as SGLT inhibitors for treatment of diabetes and obesity)

RN 815581-51-2 CAPLUS
CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-(1-piperidinyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 815581-53-4 CAPLUS
CN β-D-Glucopyranoside, 4'-[(2,4-dimethoxyphenyl)methyl]-1'-(1-methylethyl)[1,5'-bi-1H-pyrazol]-3'-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:486406 CAPLUS
DN 141:47334
TI Preventive or remedy for diseases caused by hyperglycemia
IN Ito, Fumiaki; Shibazaki, Toshihide; Tomae, Masaki; Fushimi, Nobuhiko; Isaji, Masayuki
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2004050122 | A1 | 20040617 | WO 2003-JP15503 | 20031204 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2507665 | A1 | 20040617 | CA 2003-2507665 | 20031204 |
| | AU 2003289156 | A1 | 20040623 | AU 2003-289156 | 20031204 |
| | EP 1568380 | A1 | 20050831 | EP 2003-777222 | 20031204 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1744916 | A | 20060308 | CN 2003-80109504 | 20031204 |
| | US 20060035844 | A1 | 20060216 | US 2005-537495 | 20050603 |
| | IN 2005DN02385 | A | 20070105 | IN 2005-DN2385 | 20050603 |
| PRAI | JP 2002-352201 | A | 20021204 | | |
| | WO 2003-JP15503 | W | 20031204 | | |

AB It is intended to provide a medicinal composition containing as the active ingredient a selective SGLT1 inhibitor (for example, an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect) which exerts a sugar absorption inhibitory effect over a wide range, also has a hypoglycemic effect caused by fructose intake in usual diet and thus can show an outstanding hypoglycemic effect and which is appropriate as a preventive or a remedy for diseases caused by hyperglycemia (for example, diabetes, impaired glucose tolerance, diabetic complications or obesity).
IT 705445-35-8P, 3-(β-D-Glucopyranosyloxy)-4-[[4-(2-guanidinoethoxy)-2-methylphenyl]methyl]-5-indolyl-1H-pyrazole
RL: PAC (Pharmacological activity); PPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(SGLT1 inhibitors as preventives or remedies for diseases caused by hyperglycemia)
RN 705445-35-8 CAPLUS
CN Guanidine, [2-[4-[[3-(β-D-glucopyranosyloxy)-5-(1H-indol-1-yl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 705445-15-4P 705445-20-1P 705445-25-6P,
3-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[[4-(2-acetoxyethoxy)-2-methylphenyl]methyl]-5-indolyl-1H-pyrazole
705445-30-3P 705445-45-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(SGLT1 inhibitors as preventives or remedies for diseases caused by hyperglycemia)
RN 705445-15-4 CAPLUS
CN β-D-Glucopyranoside, 5-(1H-indol-1-yl)-4-[[2-methyl-4-[2-(phenylmethoxy)ethoxy]phenyl]methyl]-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.



RN 705445-20-1 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(2-hydroxyethoxy)-2-methylphenyl]methyl]-5-(1H-indol-1-yl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.



RN 705445-25-6 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-[2-(acetyloxy)ethoxy]-2-methylphenyl]methyl]-5-(1H-indol-1-yl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.



RN 705445-30-3 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(2-aminoethoxy)-2-methylphenyl]methyl]-5-(1H-indol-1-yl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.



RN 705445-45-0 CAPLUS
CN Carbamic acid, [imino[[2-[4-[[3-(1H-indol-1-yl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]-3-

methylphenoxy]ethyl]amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:311011 CAPLUS
DN 140:321649
TI Preparation of pyrazolyl glycoside derivatives as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters
IN Fujikura, Hideki; Kikuchi, Norihiko; Tazawa, Shigeki; Yamato, Tokuhisa; Isaji, Masayuki
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2004031203 | A1 | 20040415 | WO 2003-JP12477 | 20030930 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2500873 | A1 | 20040415 | CA 2003-2500873 | 20030930 |
| AU 2003272903 | A1 | 20040423 | AU 2003-272903 | 20030930 |
| EP 1550668 | A1 | 20050706 | EP 2003-753967 | 20030930 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| US 20060128635 | A1 | 20060615 | US 2005-529895 | 20050919 |
| PRAI JP 2002-293090 | A | 20021004 | | |
| JP 2002-330694 | A | 20021114 | | |
| JP 2002-378959 | A | 20021227 | | |
| WO 2003-JP12477 | W | 20030930 | | |

OS MARPAT 140:321649
GI




I II

AB The title compds. [I; R = each (un)substituted C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; R1 = H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; one of Q0 and T0 = α- or β-D-glucopyranosyloxy or -mannopyranosyloxy or β-D-deoxyglucopyranosyloxy- and the other = (CH2)nAr; wherein Ar = each (un)substituted C6-10 aryl or C1-9 heteroaryl; n = an integer of 0-2] or pharmacol. acceptable salts or prodrugs thereof are prepared Also disclosed are medicinal composition containing the compound I, medicinal use thereof, and intermediates in producing the same. These compds. exerts an excellent effect of inhibiting human 1,5-anhydroglucitol/fructose/mannose transporters and inhibit reabsorption or cellular uptake of glucose, fructose, and mannose in kidney or absorption of these saccharide small intestine and inhibit the increase in blood sugar. Therefore, they are useful as preventives, progress inhibitors or remedies for a disease caused by the over intake of at least one saccharide selected from among glucose, fructose, and mannose or a disease caused by hyperglycemia (diabetic complication, diabetes, or diabetic nephropathy). Thus, glycosidation of 1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1,2-dihydro-3H-pyrazol-3-one by acetobromo-α-D-glucose in the presence of benzyltributylammonium bromide in a mixture of CH2Cl2 and 5 N aqueous NaOH at room temperature for 1.5 h followed by treatment of the product with NaOMe in MeOH gave 3-(β-D-glucopyranosyloxy)-1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1H-pyrazole (II). II in vitro inhibited the uptake of [14C]methyl α-D-glucopyranoside in COS-7 cells transfected with human SMINT/PME18S-FL expression plasmid with IC50 of 92 nM.

IT 678993-32-3P 678993-33-4P 678993-34-5P
678993-35-6P 678993-36-7P 678993-37-8P
678993-38-9P 678993-39-0P 678993-40-3P
678993-41-4P 678993-42-5P 678993-43-6P
678993-44-7P 678993-45-8P 678993-46-9P
678993-47-0P 678993-48-1P 678993-49-2P
678993-50-5P 678993-51-6P 678993-52-7P
678993-53-8P 678993-54-9P 678993-55-0P
678993-56-1P 678993-57-2P 678993-58-3P
678993-59-4P 678993-60-7P 678993-61-8P
678993-62-9P 678993-63-0P 678993-64-1P
678993-65-2P 678993-66-3P 678993-67-4P
678993-68-5P 678993-69-6P 678993-70-9P
678993-71-0P 678993-72-1P 678993-73-2P
678993-74-3P 678993-75-4P 678993-76-5P
678993-77-6P 678993-78-7P 678993-79-8P
678993-80-1P 678993-81-2P 678993-82-3P
678993-83-4P 678993-84-5P 678993-85-6P
678993-86-7P 678993-87-8P 678993-88-9P
678993-89-0P 678993-90-3P 678993-91-4P
678993-92-5P 678993-93-6P 678993-94-7P
678993-95-8P 678993-96-9P 678993-97-0P
678993-98-1P 678993-99-2P 678994-00-8P
678994-01-9P 678994-02-0P 678994-03-1P
678994-04-2P 678994-05-3P 678994-06-4P
678994-07-5P 678994-08-6P 678994-09-7P
678994-10-0P 678994-11-1P 678994-12-2P
678994-13-3P 678994-14-4P 678994-15-5P

678994-23-5P 678994-24-6P 678994-25-7P
678994-26-8P 678994-48-4P 678994-49-5P
678994-50-8P 678994-51-9P 678994-52-0P
678994-53-1P 678994-54-2P 678994-55-3P
678994-56-4P 678994-57-5P 678994-58-6P
678994-59-7P 678994-60-0P 678994-61-1P
678994-62-2P 678994-63-3P 678994-64-4P
678994-65-5P 678994-66-6P 678994-67-7P
678994-68-8P 678994-69-9P 678994-70-2P
678994-71-3P 678994-72-4P 678994-73-5P
678994-74-6P 678994-75-7P 678994-76-8P
678994-77-9P 679392-47-3P 679392-48-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolyl glycoside derivs. as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters and preventives, progress inhibitors or remedies for diabetic complication, diabetes, or diabetic nephropathy)

RN 678993-32-3 CAPLUS
CN β-D-Glucopyranoside, 5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-33-4 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-34-5 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-35-6 CAPLUS
CN β-D-Glucopyranoside, 1-(1,1-dimethylethyl)-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-36-7 CAPLUS
CN β-D-Glucopyranoside, 1-(1,1-dimethylethyl)-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-37-8 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1,5-diphenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-38-9 CAPLUS
CN β-D-Glucopyranoside, 1-(4-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-39-0 CAPLUS
CN β-D-Glucopyranoside, 1-cyclohexyl-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-40-3 CAPLUS
CN β-D-Glucopyranoside, 1-cyclopentyl-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-41-4 CAPLUS
CN β-D-Glucopyranoside, 1,5-diphenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-42-5 CAPLUS
CN β-D-Glucopyranoside, 1-(4-fluorophenyl)-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-43-6 CAPLUS
CN β-D-Glucopyranoside, 1-cyclopentyl-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-44-7 CAPLUS

CN β-D-Glucopyranoside, 5-(4-fluorophenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-45-8 CAPLUS
CN β-D-Glucopyranoside, 5-(3-fluorophenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-46-9 CAPLUS
CN β-D-Glucopyranoside, 5-(2-methoxyphenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-47-0 CAPLUS
CN β-D-Glucopyranoside, 5-(3-methoxyphenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-48-1 CAPLUS
CN β-D-Glucopyranoside, 5-(4-methoxyphenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-49-2 CAPLUS
CN β-D-Glucopyranoside, 5-(4-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-50-5 CAPLUS
CN β-D-Glucopyranoside, 5-(3-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-51-6 CAPLUS
CN β-D-Glucopyranoside, 5-(3-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-52-7 CAPLUS
CN β-D-Glucopyranoside, 4-[(2-methoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-53-8 CAPLUS
CN β-D-Glucopyranoside, 4-[(3-methoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-54-9 CAPLUS
CN β-D-Glucopyranoside, 1-(3-fluorophenyl)-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-55-0 CAPLUS
CN β-D-Glucopyranoside, 1-(2-fluorophenyl)-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-56-1 CAPLUS
CN β-D-Glucopyranoside, 1-(3-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-57-2 CAPLUS
CN β-D-Glucopyranoside, 1-(2-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-58-3 CAPLUS
CN β-D-Glucopyranoside, 1-cyclobutyl-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-59-4 CAPLUS
CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-60-7 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-4-(phenylmethyl)-5-[2-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-61-8 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-4-(phenylmethyl)-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-62-9 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-4-(phenylmethyl)-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-63-0 CAPLUS
CN β-D-Glucopyranoside, 5-(2-fluorophenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-64-1 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-5-(2-methylphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-65-2 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-5-(3-methylphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-66-3 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-5-(4-methylphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-67-4 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[2-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-68-5 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-69-6 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-70-9 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(2-methylphenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-71-0 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(3-methylphenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-72-1 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(4-methylphenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-73-2 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-5-phenyl-1-propyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-74-3 CAPLUS
CN β-D-Glucopyranoside, 5-(4-ethoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-75-4 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-5-[4-(1-methylethoxy)phenyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-76-5 CAPLUS
CN β-D-Glucopyranoside, 5-(4-hydroxyphenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-77-6 CAPLUS
CN β-D-Glucopyranoside, 5-(4-butoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-78-7 CAPLUS
CN β-D-Glucopyranoside, 5-[4-(1-ethylpropoxy)phenyl]-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-79-8 CAPLUS
CN β-D-Glucopyranoside, 5-[4-(cyclopentyloxy)phenyl]-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-80-1 CAPLUS
CN β-D-Glucopyranoside, 5-[4-(1-methylethoxy)phenyl]-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-81-2 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-fluorophenyl)methyl]-5-[4-(1-methylethoxy)phenyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-82-3 CAPLUS
CN β-D-Glucopyranoside, 1-ethyl-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-83-4 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(2-methylpropyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-84-5 CAPLUS
CN β-D-Glucopyranoside, 5-(4-fluorophenyl)-4-[(4-fluorophenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-85-6 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-86-7 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(4-pentylphenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-87-8 CAPLUS
CN β-D-Glucopyranoside, 5-(4-butylphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-88-9 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(4-propylphenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-89-0 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-90-3 CAPLUS
CN β-D-Glucopyranoside, 5-(4-ethylphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-91-4 CAPLUS
CN β-D-Glucopyranoside, 5-(3,4-dimethoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-92-5 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(1-naphthalenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-93-6 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(2-naphthalenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-94-7 CAPLUS
CN β-D-Glucopyranoside, 5-(3-fluoro-4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-95-8 CAPLUS
CN β-D-Glucopyranoside, 5-[1,1'-biphenyl]-4-yl-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-96-9 CAPLUS
CN β-D-Glucopyranoside, 5-(4-methoxy-3-methylphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-97-0 CAPLUS
CN β-D-Glucopyranoside, 5-(4-ethoxyphenyl)-4-[(4-fluorophenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-98-1 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-fluorophenyl)methyl]-1-(1-methylethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-99-2 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-fluorophenyl)methyl]-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-00-8 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-01-9 CAPLUS
CN β-D-Glucopyranoside, 5-(3-hydroxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-02-0 CAPLUS
CN β-D-Glucopyranoside, 5-(2-hydroxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-03-1 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[2-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-04-2 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(methylthio)phenyl]methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-05-3 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-06-4 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-ethoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-07-5 CAPLUS
CN β-D-Glucopyranoside, 5-phenyl-4-[(4-propoxyphenyl)methyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-08-6 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(1-methylethoxy)phenyl]methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-09-7 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-butoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-10-0 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-ethylphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-11-1 CAPLUS
CN β-D-Glucopyranoside, 5-phenyl-4-[(4-propylphenyl)methyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-12-2 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(1-methylethyl)phenyl]methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-13-3 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(2-methylpropyl)phenyl]methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-14-4 CAPLUS
CN β-D-Glucopyranoside, 4-([1,1'-biphenyl]-4-ylmethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-15-5 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-5-[4-(phenylmethoxy)phenyl]-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-23-5 CAPLUS
CN β-D-Glucopyranoside, 5-cyclobutyl-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-24-6 CAPLUS
CN β-D-Glucopyranoside, 5-cyclohexyl-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-25-7 CAPLUS
CN β-D-Glucopyranoside, 5-cyclobutyl-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-26-8 CAPLUS
CN β-D-Glucopyranoside, 5-cyclohexyl-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-48-4 CAPLUS
CN β-D-Glucopyranoside, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-49-5 CAPLUS
CN β-D-Glucopyranoside, 5-(1,3-benzodioxol-5-yl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-50-8 CAPLUS
CN β-D-Glucopyranoside, 4-[(3,5-dimethoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-51-9 CAPLUS
CN β-D-Glucopyranoside, 4-[(2-ethoxy-4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-52-0 CAPLUS
CN β-D-Glucopyranoside, 4-[(2-ethoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-53-1 CAPLUS
CN β-D-Glucopyranoside, 5-(4-methoxyphenyl)-4-[(2-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678894-54-2 CAPLUS
CN β-D-Glucopyranoside, 4-[(2-ethoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678894-55-3 CAPLUS
CN β-D-Glucopyranoside, 4-[(2-ethoxy-4-methoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678894-56-4 CAPLUS
CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-5-(4-ethylphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-57-5 CAPLUS
CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-58-6 CAPLUS
CN β-D-Glucopyranoside, 5-[4-(dimethylamino)phenyl]-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-59-7 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(3-pyridinyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-60-0 CAPLUS
CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-5-[4-(dimethylamino)phenyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-61-1 CAPLUS
CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-(4-pyridinyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-62-2 CAPLUS
CN Benzoic acid, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-63-3 CAPLUS
CN Benzoic acid, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-64-4 CAPLUS
CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-(3-thienyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-65-5 CAPLUS
CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-(2-thienyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-66-6 CAPLUS
CN Benzamide, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-67-7 CAPLUS
CN Benzamide, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-68-8 CAPLUS
CN Benzamide, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-69-9 CAPLUS
CN Acetamide, 2-[4-[[3-(β-D-glucopyranosyloxy)-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-70-2 CAPLUS
CN Acetamide, 2-[4-[[5-(4-ethylphenyl)-3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-71-3 CAPLUS
CN Acetamide, 2-[4-[[3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-72-4 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(2-hydroxyethoxy)-2-methoxyphenyl]methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-73-5 CAPLUS
CN β-D-Glucopyranoside, 5-(4-ethylphenyl)-4-[[4-(2-hydroxyethoxy)-2-methoxyphenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-74-6 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(2-hydroxyethoxy)-2-methoxyphenyl]methyl]-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-75-7 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(3-hydroxypropoxy)-2-methoxyphenyl]methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-76-8 CAPLUS
CN β-D-Glucopyranoside, 5-(4-ethylphenyl)-4-[[4-(3-hydroxypropoxy)-2-methoxyphenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-77-9 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(3-hydroxypropoxy)-2-methoxyphenyl]methyl]-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 679392-47-3 CAPLUS
CN β-D-Glucopyranoside, 5-(2-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 679392-48-4 CAPLUS
CN β-D-Glucopyranoside, 5-(2-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



IT 678994-83-7P 678994-96-2P 678995-00-1P
678995-10-3P 678995-14-7P 678995-15-8P
678995-16-9P 678995-17-0P 678995-18-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolyl glycoside derivs. as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters and preventives, progress inhibitors or remedies for diabetic complication, diabetes, or diabetic nephropathy)

RN 678994-83-7 CAPLUS
CN β-D-Glucopyranoside, 5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-96-2 CAPLUS
CN β-D-Glucopyranoside, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.



RN 678995-00-1 CAPLUS
CN β-D-Glucopyranoside, 4-[(3,5-dimethoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.



RN 678995-10-3 CAPLUS
CN β-D-Glucopyranoside, 5-[4-(dimethylamino)phenyl]-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl,

2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.




RN 678995-14-7 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-hydroxy-2-methoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetrakis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




RN 678995-15-8 CAPLUS
CN β-D-Glucopyranoside, 4-[[2-methoxy-4-(1-methylethoxy)phenyl]methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetrakis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.



RN 678995-16-9 CAPLUS
CN Acetamide, 2-[3-methoxy-4-[[5-(4-methoxyphenyl)-1-(1-methylethyl)-3-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 678995-17-0 CAPLUS
CN β-D-Glucopyranoside, 5-(4-methoxyphenyl)-4-[[2-methoxy-4-[2-(phenylmethoxy)ethoxy]phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetrakis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.



RN 678995-18-1 CAPLUS
CN β-D-Glucopyranoside, 5-(4-methoxyphenyl)-4-[[2-methoxy-4-[2-(phenylmethoxy)ethoxy]phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:491188 CAPLUS
DN 139:69057
TI Preparation of carbamates as hormone-sensitive lipase inhibitors for the treatment of diabetes and related disorders
IN Bodrup, Soren; Hansen, Holger Claus; Vedso, Per; Cornelis De Jong, Johannes; Jacobsen, Poul
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 390 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2003051842 | A2 | 20030626 | WO 2002-DK853 | 20021213 |
| | WO 2003051842 | A3 | 20040603 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002351732 | A1 | 20030630 | AU 2002-351732 | 20021213 |
| | US 20030166690 | A1 | 20030904 | US 2002-319212 | 20021213 |
| | US 7067517 | B2 | 20060627 | | |
| | US 20030166644 | A1 | 20030904 | US 2002-319885 | 20021213 |
| | US 7279470 | B2 | 20071009 | | |
| | EP 1458375 | A2 | 20040922 | EP 2002-787449 | 20021213 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | CN 1602191 | A | 20050330 | CN 2002-828075 | 20021213 |
| | JP 2005518377 | T | 20050623 | JP 2003-552729 | 20021213 |
| | ZA 2004004324 | A | 20050721 | ZA 2004-4324 | 20040602 |
| PRAI | DK 2001-1879 | A | 20011214 | | |
| | DK 2002-645 | A | 20020430 | | |
| | DK 2002-1000 | A | 20020629 | | |
| | DK 2002-1562 | A | 20021011 | | |
| | US 2002-346909P | P | 20020103 | | |
| | US 2002-384253P | P | 20020510 | | |
| | US 2002-393066P | P | 20020628 | | |
| | US 2002-418481P | P | 20021015 | | |
| | WO 2002-DK853 | W | 20021213 | | |

OS MARPAT 139:69057
GI



I II

AB Title compds. I [wherein R1 = H or (un)substituted (cyclo)alkyl or alkenyl; R2 = (un)substituted (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or NR1R2 = heterocyclyl; X = O or S; L = a hydrolyzable group; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, racemates, or polymorphs thereof] were prepared as inhibitors of hormone-sensitive lipase (HSL). For example, esterification of morpholine-4-carbonyl chloride with 4-(3,5-dichloropyridin-4-yloxy)phenol in the presence of DABCO in THF gave II, which showed 88% inhibition of HSL at a concentration of 10 μM. Thus, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable, such as diabetes (no data).

IT 548767-36-8P, N-Methyl-N-phenylcarbamic acid 4-benzyl-5-(4-methoxyphenyl)-3-(4-methylphenyl)pyrazol-1-yl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(lipase inhibitor; preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)

RN 548767-36-8 CAPLUS

CN 1H-Pyrazole, 5-(4-methoxyphenyl)-3-(4-methylphenyl)-1-[[(methylphenylamino)carbonyl]oxy]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 548767-37-9, 1-Hydroxy-4-benzyl-5-(4-methoxyphenyl)-3-(4-methylphenyl)pyrazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)

RN 548767-37-9 CAPLUS

CN 1H-Pyrazole, 1-hydroxy-5-(4-methoxyphenyl)-3-(4-methylphenyl)-4-(phenylmethyl)- (CA INDEX NAME)




L4 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:491187 CAPLUS
DN 139:69056
TI Preparation of carbamates as hormone-sensitive lipase inhibitors for the treatment of diabetes and related disorders
IN Ebdrup, Soren; Cornelis De Jong, Johannes; Jacobsen, Poul; Hansen, Holger Claus; Vedso, Per
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 519 pp.
CODEN: PIXXD2
DT Patent
LA English
PAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2003051841 | A2 | 20030626 | WO 2002-DK852 | 20021213 |
| | WO 2003051841 | A3 | 20040624 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2468413 | A1 | 20030626 | CA 2002-2468413 | 20021213 |
| | AU 2002351731 | A1 | 20030630 | AU 2002-351731 | 20021213 |
| | US 20030166690 | A1 | 20030904 | US 2002-319212 | 20021213 |
| | US 7067517 | B2 | 20060627 | | |
| | US 20030166644 | A1 | 20030904 | US 2002-319885 | 20021213 |
| | US 7279470 | B2 | 20071009 | | |
| | EP 1458374 | A2 | 20040922 | EP 2002-787448 | 20021213 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | CN 1602191 | A | 20050330 | CN 2002-828075 | 20021213 |
| | BR 2002014967 | A | 20050510 | BR 2002-14967 | 20021213 |
| | JP 2005518376 | T | 20050623 | JP 2003-552728 | 20021213 |
| | HU 2005001011 | A2 | 20060130 | HU 2005-1011 | 20021213 |
| | RU 2317981 | C2 | 20080227 | RU 2004-121461 | 20021213 |
| | ZA 2004004324 | A | 20050721 | ZA 2004-4324 | 20040602 |
| | IN 2004CN01295 | A | 20070727 | IN 2004-CN1295 | 20040611 |
| | MX 2004PA05790 | A | 20040913 | MX 2004-PA5790 | 20040614 |
| | NO 2004002962 | A | 20040908 | NO 2004-2962 | 20040713 |
| PRAI | DK 2001-1879 | A | 20011214 | | |
| | DK 2002-645 | A | 20020430 | | |
| | DK 2002-1000 | A | 20020629 | | |
| | DK 2002-1562 | A | 20021011 | | |
| | US 2002-346909P | P | 20020103 | | |
| | US 2002-384253P | P | 20020510 | | |
| | US 2002-393068P | P | 20020628 | | |
| | US 2002-418481P | P | 20021015 | | |
| | WO 2002-DK852 | W | 20021213 | | |

OS MARPAT 139:69056
GI



I II

AB Title compds. I [wherein R1 = H or (un)substituted (cyclo)alkyl or alkenyl; R2 = (un)substituted (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or NR1R2 = heterocyclyl; X = O or S; L = a hydrolyzable group; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, racemates, or polymorphs thereof] were prepared as inhibitors of hormone-sensitive lipase (HSL). For example, esterification of morpholine-4-carbonyl chloride with 4-(3,5-dichloropyridin-4-yloxy)phenol in the presence of DABCO in THF gave II, which showed 88% inhibition of HSL at a concentration of 10 μM. Thus, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable, such as diabetes (no data).

IT 548767-36-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(lipase inhibitor; preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)

RN 548767-36-8 CAPLUS

CN 1H-Pyrazole, 5-(4-methoxyphenyl)-3-(4-methylphenyl)-1-[[(methylphenylamino)carbonyl]oxy]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 548767-37-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)

RN 548767-37-9 CAPLUS

CN 1H-Pyrazole, 1-hydroxy-5-(4-methoxyphenyl)-3-(4-methylphenyl)-4-(phenylmethyl)- (CA INDEX NAME)



L4 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:279804 CAPLUS
DN 138:294714
TI Organic electroluminescent device using pyrazole or pyrazoline
IN Suzuki, Koichi; Ueno, Kazunori; Senoo, Akihiro
PA Canon Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
PAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI JP 2003109765 | A | 20030411 | JP 2001-300548 | 20010928 |
| PRAI JP 2001-300548 | | 20010928 | | |

OS MARPAT 138:294714
GI



I

AB The invention refers to an organic electroluminescent device comprising pyrazole or pyrazoline I [R1 = H, alkyl, (un)substituted aralkyl, aryl, heterocyclic, condensed polycyclic aromatic or heterocyclic; Ar1-3 = (un)substituted aryl, heterocyclic, condensed polycyclic aromatic or heterocyclic; at least two of R1, Ar1-3 are (un)substituted condensed polycyclic aromatic or heterocyclic groups].
IT 504414-91-9
RL: DEV (Device component use); USES (Uses)
(organic electroluminescent device using pyrazole or pyrazoline)
RN 504414-91-9 CAPLUS
CN 1H-Pyrazole, 1-(1-naphthalenyl)-3,5-di-3-perylenyl-4-(phenylmethyl)- (CA INDEX NAME)




L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:855864 CAPLUS
DN 139:214344
TI Product class 1: pyrazoles
AU Stanovnik, B.; Svete, J.
CS Faculty of Chemistry and Chemical Technology, Division of Organic Chemistry, Ljubljana, 61000, Slovenia
SO Science of Synthesis (2002), 12, 15-225
CODEN: SSCYJ9
PB Georg Thieme Verlag

DT Journal; General Review
LA English
AB A review. Methods for preparing pyrazoles are reviewed including cyclization, ring transformation, aromatization and substituent modifications.
IT 118472-50-7P 371772-77-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrazoles via cyclization, ring transformation, aromatization and substituent modifications)
RN 118472-50-7 CAPLUS
CN 1H-Pyrazole, 1,3,5-triphenyl-4-(phenylmethyl)- (CA INDEX NAME)

RN 371772-77-9 CAPLUS
CN 1H-Pyrazole, 5-(4-methylphenyl)-1,3-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)



RE.CNT 909 THERE ARE 909 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:171866 CAPLUS
DN 136:232313
TI Preparation of pyrimidine derivatives as G protein-coupled receptor kinase (GRK) inhibitors
IN Fukumoto, Shoji; Watanabe, Toshifumi; Ikeda, Shota
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2002018350 | A1 | 20020307 | WO 2001-JP7397 | 20010829 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2001082520 | A5 | 20020313 | AU 2001-82520 | 20010829 |
| | JP 2002145778 | A | 20020522 | JP 2001-259683 | 20010829 |
| PRAI | JP 2000-264499 | A | 20000829 | | |
| | WO 2001-JP7397 | W | 20010829 | | |

OS MARPAT 136:232313
GI



I

AB Disclosed are novel GRK inhibitors which contains compds. represented by the formula (I), a salt thereof, or a prodrug comprising either of these (wherein ring A represents optionally further substituted nitrogen-containing heterocycle; R1 and R2 each represents optionally substituted amino; and X represents a spacer comprising a linear part constituted of one to four atoms, provided that R1 may be bonded to R2 or/and X to form a ring). They are useful as preventives/remedies for cardiac failure. Thus, 5.48 g K2CO3 and 7.52 g 2-aminophenyl 2-nitrophenyl sulfide were added to a suspension of 5.61 g 4-amino-5-bromomethyl-2-methylpyrimidine hydrobromide in 40 mL acetone at room temperature and stirred at 65° for 64 h to give 2.36 g N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-[2-[(2-nitrophenyl)thio]phenyl]amine (II). All 10 compds. tested including II at 30 μM inhibited 30% human GRK2 expressed by human GRK2 gene in COS-7 cells. A capsule and a tablet formulation containing II were also prepared

IT 403515-13-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as G protein-coupled receptor kinase (GRK) inhibitors for prevention and/or treatment for cardiac failure)

RN 403515-13-9 CAPLUS

CN Benzamide, N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-4-[(3,5-diphenyl-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:658144 CAPLUS
DN 135:344418

TI Regioselective Synthesis of Polysubstituted Pyrazoles and Isoxazoles
AU Katritzky, Alan R.; Wang, Mingyi; Zhang, Suoming; Voronkov, Michael V.; Steel, Peter J.
CS Department of Chemistry Center for Heterocyclic Compounds, University of Florida, Gainesville, FL, 32611-7200, USA
SO Journal of Organic Chemistry (2001), 66(20), 6787-6791
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 135:344418
AB A regioselective synthesis has been developed for the preparation of unsym. 1,3,5-triaryl-4-alkylpyrazolines and -pyrazoles by treatment of α-benzotriazolyl-α,β-unsatd. ketones with monosubstituted hydrazines followed by alkylation at the 4-position of the pyrazoline ring. Reaction of α-benzotriazolyl-α,β-unsatd. ketones with hydroxylamine gives 3,5-disubstituted isoxazoles regioselectively.
IT 371772-77-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselective synthesis of polysubstituted pyrazoles and isoxazoles)
RN 371772-77-9 CAPLUS
CN 1H-Pyrazole, 5-(4-methylphenyl)-1,3-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:117030 CAPLUS
DN 132:166234
TI Preparation of estrogen receptor modulating pyrazoles
IN Huebner, Verena D.; Lin, Xiaodong; James, Ian; Chen, Liya; Desai, Manoj; Krywult, Beata; Singh, Rajinder; Wang, Liang
PA Chiron Corp., USA
SO PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2000007996 | A2 | 19990806 | WO 1999-US17799 | 19990806 |
| WO 2000007996 | A3 | 20000831 | | |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 9954677 | A | 20000228 | AU 1999-54677 | 19990806 |
| EP 1102753 | A2 | 20010530 | EP 1999-940917 | 19990806 |
| EP 1102753 | B1 | 20070228 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY | | | | |
| US 6291505 | B1 | 20010918 | US 1999-369747 | 19990806 |
| JP 2002522422 | T | 20020723 | JP 2000-563630 | 19990806 |
| AT 355279 | T | 20060315 | AT 1999-940917 | 19990806 |
| ES 2281186 | T3 | 20070916 | ES 1999-940917 | 19990806 |
| US 20020111374 | A1 | 20020815 | US 2001-954039 | 20010918 |
| US 20040034081 | A9 | 20040219 | | |

| | | | | | |
|---|---|---|---|---|---|
| | US 6727273 | B2 | 20040427 | | |
| | US 20040077701 | A1 | 20040422 | US 2003-461914 | 20030612 |
| | US 39708 | E1 | 20070626 | US 2004-757347 | 20040113 |
| PRAI | US 1998-95772P | P | 19980807 | | |
| | US 1998-95773P | P | 19980807 | | |
| | US 1999-369747 | A3 | 19990806 | | |
| | WO 1999-US17799 | W | 19990806 | | |
| | US 2001-954039 | A1 | 20010918 | | |
| OS | MARPAT 132:166234 | | | | |
| GI | | | | | |

I

II

AB The title compds. [I and II; R1, R3 = alkyl, aryl, heteroaryl, etc.; R2 = H, halo, CN, etc.; R4 = H, CO2H, CHO, etc.] which have been found to have unexpected and surprising activity in modulating estrogen receptor activity, and therefore are useful for treating or preventing estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease, were prepared E.g., a multi-step synthesis of II [R1 = Ph2CH; R2 = Et; R3 = 4-HOC6H4; R4 = Me], starting with 4'-methoxybutyrylphenone and 2,2-diphenylacetyl chloride, was given (no data for intermediates). Biol. data for compds. I and II were presented.

IT 258845-58-8P 258845-59-9P 258845-60-2P
258845-61-3P 258845-99-7P 258846-01-4P
258846-03-6P 258846-05-8P 258848-04-3P
258848-17-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of estrogen receptor modulating pyrazoles)

RN 258845-58-8 CAPLUS

CN Phenol, 4,4'-[1-(4-bromophenyl)-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)



RN 258845-59-9 CAPLUS

CN Phenol, 4,4'-[1-(4-chloro-2-methylphenyl)-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)



RN 258845-60-2 CAPLUS
CN Phenol, 4,4'-[1-(3-chlorophenyl)-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis-
(9CI) (CA INDEX NAME)



RN 258845-61-3 CAPLUS
CN Phenol, 4,4'-[1-(4-chlorophenyl)-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis-
(9CI) (CA INDEX NAME)



RN 258845-99-7 CAPLUS
CN Phenol, 3-[[3,5-bis(4-hydroxyphenyl)-4-(phenylmethyl)-1H-pyrazol-1-
yl]methyl]- (CA INDEX NAME)



RN 258846-01-4 CAPLUS
CN Phenol, 4,4'-[1-[4-(methylsulfonyl)phenyl]-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)



RN 258846-03-6 CAPLUS
CN Phenol, 4,4'-[1-(pentafluorophenyl)-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)



RN 258846-05-8 CAPLUS
CN Phenol, 4,4'-[4-(phenylmethyl)-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)



RN 258848-04-3 CAPLUS
CN Phenol, 4,4'-[1-cyclobutyl-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)



RN 258848-17-8 CAPLUS
CN Phenol, 4-[1-(2-fluorophenyl)-5-(4-methylphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



L4 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:780010 CAPLUS
DN 130:125020
TI Synthesis of potassium tris(substituted pyrazolyl) hydroboride
AU Guo, Shengi; Li, Xianjun; Yin, Yuanqi
CS Department of Chemistry, Sichuan University, Chengdu, 610064, Peop. Rep. China
SO Huaxue Yanjiu Yu Yingyong (1998), 10(4), 406-409
CODEN: HYYIFM; ISSN: 1004-1656
PB Huaxue Yanjiu Yu Yingyong Bianjibu
DT Journal

LA Chinese
GI



AB Potassium pyrazole hydroboride derivs. (I; R1 = CH3, Ph; R3= thiophenyl, Ph) were synthesized and fully characterized. The position-isomer and 1H NMR spectra of these compds. were also discussed.
IT 219863-66-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of potassium tris(substituted pyrazolyl) hydroboride)
RN 219863-66-8 CAPLUS
CN 1H-Pyrazole, 3-phenyl-4-(phenylmethyl)-5-(2-thienyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:44662 CAPLUS
DN 126:59751
OREF 126:11733a,11736a
TI Preparation of di- and tricarboxybenzamides and analogs as squalene synthetase and protein farnesyltransferase inhibitors
IN Baker, William R.; Rosenberg, Saul H.; Fung, K. L. Anthony; Rockway, Todd W.; Fakhoury, Stephen A.; Garvey, David S.; Donner, B. Gregory; O'Connor, Stephen J.; Prasad, Rajnandan N.; Shen, Wang; Stout, David M.; Sullivan, Gerard M.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 241 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9634851 | A1 | 19961107 | WO 1996-US6193 | 19960502 |
| W: AU, CA, JP, KR, MX | | | | |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| US 5783593 | A | 19980721 | US 1996-633262 | 19960429 |
| AU 9656731 | A | 19961121 | AU 1996-56731 | 19960502 |
| PRAI US 1995-429095 | A | 19950503 | | |
| US 1996-633262 | A | 19960429 | | |
| US 1993-147708 | B2 | 19931104 | | |
| US 1994-289711 | B2 | 19940909 | | |
| US 1994-322783 | B2 | 19941018 | | |
| WO 1996-US6193 | W | 19960502 | | |

OS MARPAT 126:59751
GI



I II

AB Title compds. [e.g., I; A1 = ZCONR1R2; A2,A4, and A5 or A2 and A4 or A3and A4 = (protected) CO2H and the other An = H; R1 = (chloro)benzyl, (CH2)2-4Ph, CH2C6H4(OPh)-4; R2 = (CH2)1-2C6H4(OPh)-4; Z = bond, NR, O; R = H, (cyclo)alkyl, aralkyl, cycloalkylalkyl] were prepared Thus, 4-(PhO)C6H4CHO was reductively aminated by H2CH2Ph and the product amidated by 1,2,4,5-benzenetetracarboxylic dianhydride to give title compound II. Data for in vitro inhibition of protein farnesyltransferase by selected I were given.

IT 185049-89-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of di- and tricarboxybenzamides and analogs as squalene synthetase and protein farnesyltransferase inhibitors)

RN 185049-89-2 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 4-[5-(4-phenoxyphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



IT 185051-22-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of di- and tricarboxybenzamides and analogs as squalene synthetase and protein farnesyltransferase inhibitors)

RN 185051-22-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 4-[5-(4-phenoxyphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl]-, dimethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:59269 CAPLUS
DN 116:59269
OREF 116:10257a,10260a
TI Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic
AU Meanwell, Nicholas A.; Rosenfeld, Michael J.; Wright, J. J. Kim; Brassard, Catherine L.; Buchanan, John O.; Federici, Marianne E.; Fleming, J. Stuart; Seiler, Steven M.
CS Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, 06492, USA
SO Journal of Medicinal Chemistry (1992), 35(2), 389-97
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 116:59269
GI



I

AB A series of phenylated pyrazolealkanoic acids, e.g., I (R = (CH2)nCO2H, n = 5-10, R1, R3 = H, Ph, R2 = Ph, PhCH2, Et; R = (CH2)6XCH2CO2H, X = O, S, S(O), SO2, R1 = R2 = R3 = Ph) and related derivs. were prepared as inhibitors of ADP-induced human platelet aggregation. 3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (II), with an IC50 of 0.4 μM, was the most potent inhibitor. Biochem. studies determined that II increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concentration-dependent fashion. Displacement of [3H]iloprost by II from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biol. action. Structure-activity studies demonstrated that the min. structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an ω-alkanoic acid side chain 8 or 9 atoms long. Potency depended upon both side-chain length and its topol. relationship with the two Ph rings.
IT 137743-31-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(blood platelet aggregation inhibiting activity of)
RN 137743-31-8 CAPLUS
CN 1H-Pyrazole-1-nonanoic acid, 3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)



L4 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1989:94258 CAPLUS
DN 110:94258
OREF 110:15563a,15566a
TI Cycloaddition of some diarylnitrilimines to various 2-arylidene-1-indanones. Regio- and diastereochemistry of spiropyrazoline synthesis
AU Kerbal, Abdelali; Tshiamala, Kabula; Vebrel, Joel; Laude, Bernard
CS Fac. Sci., Univ. Franche-Comte, Besancon, 25030, Fr.
SO Bulletin des Societes Chimiques Belges (1988), 97(2), 149-61
CODEN: BSCBAG; ISSN: 0037-9646
DT Journal
LA French
OS CASREACT 110:94258
GI



I II

AB 1,3-Dipolar cycloaddn. of the title indanones I (R1 = H, Me; R2 = H, Me, Ph; R = H, Me, OMe) with 4-R4C6H4C.tplbond.N+N-Ph (R4 = H, Me, OMe, Cl, NO2) gave spiropyrazolines II. The cycloaddn. was regio- and stereospecific. Thus, the dipole approaches from the less hindered face of the dipolarophile.

IT 118472-50-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 118472-50-7 CAPLUS

CN 1H-Pyrazole, 1,3,5-triphenyl-4-(phenylmethyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1982:16078 CAPLUS

DN 96:16078

OREF 96:2667a,2670a

TI Composition containing a pyrazolium salt for retarding the growth of sunflower

IN Shafer, Neal E.; Bhalla, Prithvi Raj

PA American Cyanamid Co. , USA

SO Fr. Demande, 28 pp.
CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| FR 2475853 | A1 | 19810821 | FR 1981-3167 | 19810218 |
| CA 1151890 | A1 | 19830816 | CA 1981-369468 | 19810128 |
| BR 8100964 | A | 19810825 | BR 1981-964 | 19810218 |
| AU 8167409 | A | 19810827 | AU 1981-67409 | 19810218 |
| ZA 8101086 | A | 19820331 | ZA 1981-1086 | 19810218 |
| ES 499545 | A1 | 19820901 | ES 1981-499545 | 19810218 |
| HU 27555 | A2 | 19831028 | HU 1981-390 | 19810218 |

PRAI US 1980-122642 A 19800219

GI



I II

AB The pyrazolium salts I or II (R1 and R2 C1-3 alkyl or Ph; R4 = H, OH, C1-18 alkyl, haloalkyl, alkoxy, PhCH2, substituted Ph, etc.; R3 and R5 = C1-12 alkyl, alkoxy, cycloalkyl, halo, NH2, PhNH, EtO, naphthyloxy, heterocyclic radical, etc.; R6 = H or Me; X = acetate, sulfate, etc.; m = 1, 2, or 3) are growth inhibitors for sunflower. Thus, preplant 1,2-dimethyl-3,5-diphenylpyrazolium Me sulfate [43222-48-6] (0.25 kg/ha) decreased the height of sunflower by 69.6%.

IT 80068-90-2
RL: BIOL (Biological study)
(plant growth inhibitor, for sunflower)

RN 80068-90-2 CAPLUS

CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 59876-16-3
CMF C24 H23 N2



CM 2

CRN 14808-79-8
CMF O4 S

L4 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1977:89813 CAPLUS
DN 86:89813
OREF 86:14185a,14188a
TI Diphenylpyrazolium salts
IN Cross, Barrington; Walworth, Bryant L.
PA American Cyanamid Co., USA
SO Ger. Offen., 39 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI DE 2618421 | A1 | 19761118 | DE 1976-2618421 | 19760427 |
| US 3958001 | A | 19760518 | US 1975-574067 | 19750502 |
| US 4017298 | A | 19770412 | US 1975-574068 | 19750502 |
| ZA 7602247 | A | 19770427 | ZA 1976-2247 | 19760414 |
| PRAI US 1975-574067 | A | 19750502 | | |
| US 1975-574068 | A | 19750502 | | |

GI



AB The title compds. I (R = Me, Et, Pr, Me2CH, HO2CCH2, CH2:CHCH2, HC.tplbond.CCH2, PhCH2; X = I, ClO4, MeSO4, HSO4), useful as fungicides and herbicides, are prepared by quaternization of the appropriate pyrazoles which are obtained by cyclocondensation of PhCOCHRCOPh with MeNHNH2. Thus, reaction of 1,4-dimethyl-3,5-diphenylpyrazole with Me2SO4 in PhMe at 80°, followed by 3 hr stirring at 100°, gives 72% I (R = Me, X = MeSO4). 1,2,4-Trimethyl-3,5-dicyclohexylpyrazolium methyl sulfate is prepared similarly.

IT 59876-17-4P 59876-18-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and herbicidal activity of)

RN 59876-17-4 CAPLUS
CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 59876-16-3
CMF C24 H23 N2



CM 2

CRN 14996-02-2
CMF H O4 S

RN 59876-18-5 CAPLUS
CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 59876-16-3
CMF C24 H23 N2



CM 2

CRN 14797-73-0
CMF Cl O4

IT 59876-05-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and quaternization of)
RN 59876-05-0 CAPLUS
CN 1H-Pyrazole, 1-methyl-3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)



L4 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1976:560086 CAPLUS
DN 85:160086
OREF 85:25629a,25632a
TI 4-Alkyl-1,2-dimethyl-3,5-diphenylpyrazolium salts and derivatives as fungicidal agents
IN Cross, Barrington; Walworth, Bryant L.
PA American Cyanamid Co., USA
SO U.S., 7 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 3963741 | A | 19760615 | US 1975-619092 | 19751002 |
| US 3958001 | A | 19760518 | US 1975-574067 | 19750502 |
| PRAI US 1975-574067 | A3 | 19750502 | | |

GI



AB Pyrazolium salts I (R = Me, Pr, CHMe2, pentyl, CH2Ph, X = ClO4; R = Me, Et, X = MeSO4; R = CH2C.tplbond.CH, CH2Ph, allyl, X = HSO4; R = CH2CO2Et, X = I) were prepared by alkylating NaCHBz2, cyclizing RCHBz2 with MeNHNH2, treating the pyrazoles with Me2SO4 and optionally changing the anion. I controlled powder mildews on cucumbers, wheat, and barley at ≤500 ppm.
IT 59876-17-4P 59876-18-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and fungicidal activity of)

RN 59876-17-4 CAPLUS
CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 59876-16-3
CMF C24 H23 N2



CM 2

CRN 14996-02-2
CMF H O4 S

RN 59876-18-5 CAPLUS
CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, perchlorate
(9CI) (CA INDEX NAME)

CM 1

CRN 59876-16-3
CMF C24 H23 N2



CM 2

CRN 14797-73-0
CMF Cl O4

IT 59876-05-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and quaternization of)
RN 59876-05-0 CAPLUS

CN 1H-Pyrazole, 1-methyl-3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)

L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1976:463065 CAPLUS
DN 85:63065
OREF 85:10157a,10160a
TI 4-Alkyl-1,2-dimethyl-3,5-diphenylpyrazolium salts and derivatives as fungicidal agents
IN Cross, Barrington; Walworth, Bryant L.
PA American Cyanamid Co., USA
SO U.S., 7 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 3958001 | A | 19760518 | US 1975-574067 | 19750502 |
| | US 3963741 | A | 19760615 | US 1975-619092 | 19751002 |
| | IL 49410 | A | 19800630 | IL 1976-49410 | 19760413 |
| | AU 7612987 | A | 19771020 | AU 1976-12987 | 19760414 |
| | AU 503523 | B2 | 19790906 | | |
| | CA 1078850 | A1 | 19800603 | CA 1976-250620 | 19760421 |
| | GB 1543338 | A | 19790404 | GB 1976-16439 | 19760422 |
| | FI 7601159 | A | 19761103 | FI 1976-1159 | 19760427 |
| | DE 2618421 | A1 | 19761118 | DE 1976-2618421 | 19760427 |
| | BE 841231 | A1 | 19761028 | BE 1976-166527 | 19760428 |
| | NL 7604597 | A | 19761104 | NL 1976-4597 | 19760429 |
| | FR 2309539 | A1 | 19761126 | FR 1976-12809 | 19760429 |
| | CS 191170 | B2 | 19790629 | CS 1976-2833 | 19760429 |
| | DK 7601944 | A | 19761103 | DK 1976-1944 | 19760430 |
| | SE 7605011 | A | 19761103 | SE 1976-5011 | 19760430 |
| | DD 127656 | A5 | 19771005 | DD 1976-192622 | 19760430 |
| | SU 683601 | A3 | 19790830 | SU 1976-2354750 | 19760430 |
| | PL 107282 | B1 | 19800229 | PL 1976-189201 | 19760430 |
| | JP 51133265 | A | 19761118 | JP 1976-50052 | 19760504 |
| PRAI | US 1975-574067 | A3 | 19750502 | | |
| | US 1975-574068 | A | 19750502 | | |

GI



AB PhCOCH2COPh was alkylated (NaH) to give PhCOCHRCOPh (R = n-C5H11, Me, Pr, Me2CH, CH2C.tplbond.CH, Et, CH2CO2Et, CH2CH:CH2, PhCH2), which were cyclized with MeNHNH2 to give the pyrazoles I. I were converted into II (X = MeSO4, ClO4, I). At 50-950 ppm II controlled rice blast, apple scab, and powdery mildew.
IT 59876-17-4P 59876-18-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and fugicidal activity of)
RN 59876-17-4 CAPLUS
CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 59876-16-3
CMF C24 H23 N2



CM 2

CRN 14996-02-2
CMF H O4 S

RN 59876-18-5 CAPLUS
CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 59876-16-3
CMF C24 H23 N2



CM 2

CRN 14797-73-0
CMF Cl O4

IT 59876-05-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)
RN 59876-05-0 CAPLUS
CN 1H-Pyrazole, 1-methyl-3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)

L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1966:456804 CAPLUS
DN 65:56804
OREF 65:10587a-c
TI Derivatives of 4-(1-pyrazolyl)pyrimidine. II. The synthesis of 4-(3,5-diphenyl-4-alkylpyrazolyl)-5-phenylpyrimidines
AU Tsatsaronis, G. S.; Mikromastoras, E.; Halivopoulos, S.
CS Univ. Thessaloniki, Thessaloniki, Greece
SO Chim. Chronika (Athens, Greece) (1966), 31(5), 57-9
DT Journal
LA English
AB cf. CA 61, 11992b. The title compds. (I) were prepared by treating 4-hydrazino-5-phenylpyrimidine (II) with 1,3-diphenyl-2-alkyl-1,3-propanedione (III). Thus 2 g. II and 2.5 g. III (alkyl = H) were heated 20 min. at 140°, the temperature raised to 160-70° and maintained 20 min. more. The resinous product was dissolved in hot MeOH and treated with charcoal to yield 57% I (alkyl = H), m. 119-20°. Similarly prepared were the following I (alkyl, m.p., and yield given): Me, 106-8°, 49%; Et, 133-4°, 58%; PhCH2, 162°, 46%.
Using 4-hydrazino-5-(p-nitrophenyl) pyrimidine instead of II, the following 4-[(3,5-diphenyl-4-alkylpyrazol-1-yl)]-5-(p-nitrophenyl)-pyrimidines were prepared (alkyl, m.p., and % yield given): H, 214-15°, 71; Me, 192°, 70; Et, 161-2°, 62; PhCH2, 157°, 49.
IT 7052-31-5P, Pyrimidine, 4-(4-benzyl-3,5-diphenylpyrazol-1-yl)-5-(p-nitrophenyl)- 7200-69-3P, Pyrimidine, 4-(4-benzyl-3,5-diphenylpyrazol-1-yl)-5-phenyl-
RL: PREP (Preparation)
(preparation of)
RN 7052-31-5 CAPLUS
CN Pyrimidine, 4-(4-benzyl-3,5-diphenylpyrazol-1-yl)-5-(p-nitrophenyl)- (7CI, 8CI) (CA INDEX NAME)



RN 7200-69-3 CAPLUS
CN Pyrimidine, 4-(4-benzyl-3,5-diphenylpyrazol-1-yl)-5-phenyl- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1964:411116 CAPLUS
DN 61:11116
OREF 61:1786a-h,1787a-b
TI Synthetic drugs. XII. Constitution and salidiuretic effect of 3-sulfamoyl-4-chlorobenzoic acid derivatives and related compounds
AU Jucker, E.; Lindenmann, A.; Schenker, E.; Flueckiger, E.; Taeschler, M.
CS Sandoz Ltd., Basel, Switz.
SO Arzneimittel-Forschung (1963), 13(4), 269-80
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. CA 59, 6350b; 60, 15830c. A large number of 3-sulfamoyl-4-chlorobenzoic acid derivs. with the basic structures I-XIII [R, R', and R'' (if present), and m.p. of base or salt given] have been prepared, partially by known methods (CA 59, 10031a), partially by new methods, and were tested for their salidiuretic activity. I prepared were: H, H, HCl salt, 224-5°; (RR' =) 3-pyridylmethylene, 190-2°; (RR' =) 4-ClC6H4CH, 208-11°; (RR' =) PhCH, 153-4°; H, 3-pyridylmethyl, 160-2° (decomposition); H, 4-ClC6H4CH2, 149-51° (decomposition); H, PhCH2, 117-18° (decomposition). II prepared were: H, H, HCl salt, 217-19° (decomposition); (RR' =) Me2C, 217-19° (decomposition); H, 4-ClC6H4CO, 215-17°; H, Bz, 242-4°; H, PhCH2CO, 151-3°. III prepared were: Me, H, EtO, 192-4°; 4-ClC6H4, H, 4-ClC6H4, 250-1°; Ph, H, Ph, 251-3°; Ph, Et, Ph, 191-2°; Ph, PhCH2, Ph, 211-13°. IV prepared were: Me, H, 230-2°; Me, Et, 188-9°; Ph, H, 218-20°; Ph, o-ClC6H4CH2, 115-16°. V prepared were: F, Me, 136-8°; Cl, Me, 154-5°; Br, Me, 155-6°; Cl, Et, 155-6°; Cl, CH2CH2CO2H, 166-7°; Cl, Pr, 145-6°; Cl, CH2CH2CO2Me, 112-13°. VI prepared were: CHO, 161-4° (decomposition); PhNHN:CH, 236-9° (decomposition); CH2OH, 143-5° (decomposition); 4,3-Cl(H2NO2S)C6H3CO2CH2, 226-9° (decomposition); MeCH(OH), 142-4°; EtCH(OH), 131-3° (decomposition); PrCH(OH), 109-110 (decomposition). VII prepared were: Cl, CH.tplbond.CCH2, 112-13°; Cl, 2-thienylmethyl, 133-4°; Cl, cyclopentyl, 163-4°; Cl, 2-tetrahydrofurfurylmethyl, 130-1° (F analog m. 91-3°); Cl, 2-pyridylmethyl, 170-1°; Cl, 3-pyridylmethyl, 189-90°; Cl, 4-pyridylmethyl, 184-5°; Cl, cyclohexyl, 148-9°; Cl, 2-tetrahydropyranylmethyl, 161-3°; Cl, 4-FC6H4CH2, 157-8°; Cl, 4-O2NC6H4CH2, 157°; Cl, PhCH2, 121-2°; F, PhCH2, 150-1°; Cl, cycloheptyl, 135-6°; Cl, PhCH2CH2, 99-100°; Cl, cyclooctyl, 150-3°; Cl, C8H17, 85°; Cl, 4-quinolylmethyl, 244-5°; Cl, C16H33, 90-1°. VIII prepared were: 2-furfurylmethylamino, 150-2°; 2-tetrahydrofurfurylmethylamino, 169-72°; N-methyl-N'-tetrahydropyrazinyl, 220-4°; 2-(6-chlorobenzothiazolyl)amino, 333-7° (decomposition); 1-(5-methyl-1,5-diazacyclooctyl), 187-90°; N- [N'-(2-chlorophenyl)tetrahydropyrazinyl], 204-6° (3-Cl analog, 192-4°; 4-Cl analog, 192-3°). IX prepared were: H, H, 214-15° (HCl, salt, 303-5°); Me, Me, 193-5°; H, EtCO2, 208-9°; H, Me2CH, 206-7°; H, Bz, 225-7°. X prepared were: Cl, 2-oxooxazolidin-3-yl, 182-3°; F, 1,4-thiazan-4-yl, 250-2°; Cl, morpholino, 267-8°; Cl, piperidino, 230-2°; Cl, 4-methyl-1-piperazinyl, 195-6°; Cl, 1,2,3,4-tetrahydro-1-quinolinyl, 270-2°. XI prepared were: Me, CO2H, 228-31°; Me, CONH2, 199-201°; Me, CO2Et, 148-51°; Me, N-(2,6-dimethyl-1-piperidyl)carbamoyl, 306-8°; Cl, CO2H, 225-6°; Cl, MeNHNHCO, 240°; Cl, Me2NNHCO, 172°; Cl, piperidinocarbamoyl, 214°; Cl, PhNHNHCO, 188-9°; Cl, N-azacyclooctylcarbamoyl, 190-1°. XII prepared were: NH2C(S)NH, 195-7° (decomposition); NH2CONHNH, 197-9° (decomposition); NH2CONHCO, 231-4°; N-propylsultamyl, 180-2°; γ-butyrolactonyl, 153-5°; 5-(5-methyl-2,4-dioxoimidazolidinyl), 278-9°; N-butylsultamyl, 182-4°; PhNHC(S)NH, 185-7°; 2-oxo-5-enyl-1,3,4-oxadiazolin-3-yl), 278-9°; 2-oxo-3-phenyl-1,3,4-oxadiazolin-5-yl, 244-5°; BzNHNHCO, 237-9° (decomposition); PhNHN:CMe, 157-8° (decomposition); PhCH2CO2CH2, 117°. XIII prepared were: F, H2NCO, 198-9°; MeS, EtOSO2, 132-5° (decomposition); MeS, N-propylsultamyl, 193-5°; MeS, N-butylsultamyl, 155-7°; methylsulfinyl, N-butylsultamyl, 195-7°; MeSO2,

N-butylsultamyl, 216-18° (decomposition); Cl, PhNHNHSO2, 172-4° (decomposition); MeS, PhNHNHSO2, 163-5° (decomposition). Intermediate products prepared were: 4,3-Cl(H2N)C6H3COCH2CH2CO2H, m. 167-9° (decomposition); 4,3-Cl(ClO2S)C6H3COCH2CH2CO2H, m. 164-8° (decomposition); 2,4,5-Cl2(H2NO2S)C6H2COCl, m. 175-6°; 4,3-Cl(H2NO2S)C6H3SO2Cl, m. 181-3° (decomposition). The pharmacol. results obtained on rats and dogs are given in tables and in graphs. The results obtained with N-(cis-2,6-dimethyl-1-piperidyl)-3-sulfamoyl-4-chlorobenzoic acid amide (DT-327, Chlosudimeprimylium, Brinaldix) are discussed in detail.

IT 96277-00-8P, Benzenesulfonamide, 5-(4-benzyl-3,5-diphenylpyrazol-1-yl)-2-chloro-
RL: PREP (Preparation)
(preparation of)

RN 96277-00-8 CAPLUS

CN Benzenesulfonamide, 5-(4-benzyl-3,5-diphenylpyrazol-1-yl)-2-chloro- (7CI) (CA INDEX NAME)



L4 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1964:45682 CAPLUS

DN 60:45682

OREF 60:8014c-e

TI Chemistry of selenophene. XLVIII. Synthesis of di- and tri- substituted pyrazoles containing the selenophene ring

AU Yur'ev, Yu. K.; Magdesieva, N. N.; Titov, V. V.; Brysova, V. P.

CS M. V. Lomonosov State Univ., Moscow

SO Zhurnal Obshchei Khimii (1963), 33(11), 3517-19
CODEN: ZOKHA4; ISSN: 0044-460X

DT Journal

LA Unavailable

GI For diagram(s), see printed CA Issue.

AB cf. CA 60, 490g. Refluxing propionyl(2-selenophenecarbonyl)methane with N2H4.H2O in MeOH 1 hr. gave 63.5% 3-ethyl-5-(2-selenophene-yl)pyrazole (I), m. 108-9°. Similarly, butyroyl(2-selenophenecarbonyl)-methane gave 80% 3-propyl-5-(2-selenophene-yl)pyrazole, m. 90-1°, while methylacetyl(2-selenophenecarbonyl)methane gave 82% 3,4-dimethyl-5-(2-selenophene-yl)pyrazole, m. 150-1°, and ethylacetyl(2-selenophenecarbonyl)methane gave 54% 3-methyl-4-ethyl-5-(2-selenophene-yl)pyrazole, m. 72-3°. α-Naphthoyl (2-selenophenecarbonyl)methane similarly gave 61.5% 3-α-naphthyl-5-(2-selenophene-yl)pyrazole, m. 72-4°, while p-tolyl(2-selenophenecarbonyl)methane gave 76% 3-p-tolyl-5-(2-selenophene-yl)-pyrazole, m. 181-1.5°, anisoyl-(2-selenophenecarbonyl)methane gave 66% 3-anisyl-5-(2-selenophene-yl)pyrazole, m. 159.5-61°, and picolinoyl-(2-selenophenecarbonyl)methane gave 76% 3-α-pyridyl-5-(2-selenophene-yl)pyrazole, m. 146-7°. Refluxing 1,3-dibenzoyl-1,3-bis(2-selenophenecarbonyl)methane with N2H4.H2O in dioxane 2.5 hrs. gave 30.5% bis[3-phenyl-5-(2-selenophene-yl)pyrazol-4-yl]methane, m. 122-5°.

IT 102346-85-0P, Pyrazole, 4,4'-methylenebis[3(or 5)-phenyl-5(or 3)-selenophene-2-yl-
RL: PREP (Preparation)
(preparation of)

RN 102346-85-0 CAPLUS

CN Pyrazole, 4,4'-methylenebis[3(or 5)-phenyl-5(or 3)-selenophene-2-yl- (7CI) (CA INDEX NAME)


HN
N
Ph
Se
CH2
Se
Ph
N
H
N